{
    "Clinical Trial ID": "NCT02435680",
    "Intervention": [
        "INTERVENTION 1: ",
        "  All MCS110+Carboplatin+Gemcitabine",
        "  experimental. all MCS110 treated patients, with 10mg/kg intravenous infusion, on day 1 and days 1 & 8",
        "INTERVENTION 2: ",
        "  Carboplatin+Gemcitabine",
        "  comparator. Gemcitabine: Intravenous infusion 1000 mg/m2 Days 1 & 8 Carboplatin: Intravenous infusion AUC 2 Days 1 & 8"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Adult women ( 18 years of age) with advanced TNBC.",
        "  Histological or cytological evidence of estrogen-receptor negative (ER-), progesterone receptor negative (PgR-) and human epidermal growth factor-2 receptor negative (HER2-) Breast Cancer by local laboratory testing, based on last available tumor tissue.",
        "  ER/PgR negativity to follow local guidelines",
        "  If IHC HER2 2+, a negative FISH test is required",
        "  A pre-treatment tumor biopsy demonstrating high TAM content as assessed per the central laboratory",
        "Patients must have:",
        "  At least one measurable lesion per RECIST 1.1. (Note: Measurable lesions include lytic or mixed (lytic + blastic) bone lesions, with an identifiable soft tissue component that meets the measurability criteria)",
        "Exclusion Criteria:",
        "  Prior chemotherapy for advanced BC. Previous adjuvant/neoadjuvant chemotherapy is allowed (carboplatin, cisplatin or gemcitabine only if > 12 months has passed since last administration).",
        "  Therapy for underlying malignancy within 2 weeks prior to start of study treatment:",
        "  Chemotherapy, biologic therapy (antibodies and biologically targeted small molecules)",
        "  Radiotherapy",
        "  Major surgery",
        "  Patients receiving concomitant immunosuppressive agents or chronic corticosteroids (  10 mg of prednisone or equivalent) at the time of first study dose.",
        "  Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening.",
        "  Known history of human immunodeficiency virus or active infection with hepatitis virus or any uncontrolled active systemic infection.",
        "  Patients with the following laboratory values during screening and on Day 1 predose:",
        "  Absolute Neutrophil Count (ANC) < 1.5x109/L",
        "  Hemoglobin < 9 g/dL",
        "  Platelets < 100x109/L",
        "  Serum creatinine > 1.5 x ULN",
        "  Serum total bilirubin > 1.5 x ULN",
        "  AST/SGOT and ALT/SGPT > 3.0 x ULN"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Progression Free Survival (PFS) as Per RECIST v1.1 (by Local Investigator Assessment)",
        "  PFS Results presented for all MCS110 treated patients (with and without day 8 dose), in line with phase 2 study design.",
        "  Time frame: 4 years",
        "Results 1: ",
        "  Arm/Group Title: All MCS110+Carboplatin+Gemcitabine",
        "  Arm/Group Description: experimental. all MCS110 treated patients, with 10mg/kg intravenous infusion, on day 1 and days 1 & 8",
        "  Overall Number of Participants Analyzed: 34",
        "  Median (90% Confidence Interval)",
        "  Unit of Measure: months  5.6        (4.5 to 8.7)",
        "Results 2: ",
        "  Arm/Group Title: Carboplatin+Gemcitabine",
        "  Arm/Group Description: comparator. Gemcitabine: Intravenous infusion 1000 mg/m2 Days 1 & 8 Carboplatin: Intravenous infusion AUC 2 Days 1 & 8",
        "  Overall Number of Participants Analyzed: 16",
        "  Median (90% Confidence Interval)",
        "  Unit of Measure: months  5.5        (3.5 to 7.5)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 10/19 (52.63%)",
        "  Anaemia 0/19 (0.00%)",
        "  Atypical haemolytic uraemic syndrome 1/19 (5.26%)",
        "  Thrombocytopenia 0/19 (0.00%)",
        "  Myocardial ischaemia 0/19 (0.00%)",
        "  Nausea 0/19 (0.00%)",
        "  Obstructive pancreatitis 1/19 (5.26%)",
        "  Vomiting 0/19 (0.00%)",
        "  Fatigue 0/19 (0.00%)",
        "  Generalised oedema 1/19 (5.26%)",
        "  Pyrexia 1/19 (5.26%)",
        "  Device related infection 1/19 (5.26%)",
        "Adverse Events 2:",
        "  Total: 7/15 (46.67%)",
        "  Anaemia 1/15 (6.67%)",
        "  Atypical haemolytic uraemic syndrome 0/15 (0.00%)",
        "  Thrombocytopenia 3/15 (20.00%)",
        "  Myocardial ischaemia 1/15 (6.67%)",
        "  Nausea 1/15 (6.67%)",
        "  Obstructive pancreatitis 0/15 (0.00%)",
        "  Vomiting 2/15 (13.33%)",
        "  Fatigue 1/15 (6.67%)",
        "  Generalised oedema 0/15 (0.00%)",
        "  Pyrexia 0/15 (0.00%)",
        "  Device related infection 0/15 (0.00%)"
    ]
}